Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Packer

Showing results (171-180 of 326) with videos related to

Pageof 33
Sort By:
Journal of Cardiovascular Pharmacology|May 1, 1993
Simultaneous modeling of the pharmacokinetic and pharmacodynamic properties of enalkiren (Abbott-64662, a renin inhibitor). II: A dose-ranging study in patients with congestive heart failureS K Gupta, G R Granneman, M Packer, et al.
The New England Journal of Medicine|July 26, 1990
Elevated circulating levels of tumor necrosis factor in severe chronic heart failureB Levine, J Kalman, L Mayer, et al.
The American Journal of Cardiology|October 1, 1982
Part I: pharmacologic and hemodynamic actions and interactions. Pharmacologic and hemodynamic mechanisms underlying the antianginal actions of verapamilB N Singh, C Y Chew, M A Josephson, et al.
Pigment Cell & Melanoma Research|August 18, 2009
Identification of direct transcriptional targets of (V600E)BRAF/MEK signalling in melanomaLeisl M Packer, Philip East, Jorge S Reis-Filho, et al.
Journal of the American College of Cardiology|August 1, 1983
Hemodynamic responses to combined therapy with captopril and hydralazine in patients with severe heart failureB M Massie, M Packer, J T Hanlon, et al.
The New England Journal of Medicine|July 31, 1980
Importance of left ventricular chamber size in determining the response to hydralazine in severe chronic heart failureM Packer, J Meller, N Medina, et al.
The American Journal of Cardiology|June 15, 1995
Role of endothelin in the exercise intolerance of chronic heart failureH Krum, R Goldsmith, M Wilshire-Clement, et al.
The New England Journal of Medicine|November 29, 1979
Rebound hemodynamic events after the abrupt withdrawal of nitroprusside in patients with severe chronic heart failureM Packer, J Meller, N Medina, et al.
The Australasian Journal of Dermatology|February 8, 2012
Folliculosebaceous cystic hamartoma of the ear and periauricular skinVladimir O Osipov, Peter Vincent, Andrew M Packer, et al.
The American Journal of Cardiology|March 1, 1980
Dose requirements of hydralazine in patients with severe chronic congestive heart failureM Packer, J Meller, N Medina, et al.
Pageof 33

Showing results (171-180 of 326) with videos related to

Sort By:
Pageof 33
Journal of Cardiovascular Pharmacology|May 1, 1993
Simultaneous modeling of the pharmacokinetic and pharmacodynamic properties of enalkiren (Abbott-64662, a renin inhibitor). II: A dose-ranging study in patients with congestive heart failureS K Gupta, G R Granneman, M Packer, et al.
The New England Journal of Medicine|July 26, 1990
Elevated circulating levels of tumor necrosis factor in severe chronic heart failureB Levine, J Kalman, L Mayer, et al.
The American Journal of Cardiology|October 1, 1982
Part I: pharmacologic and hemodynamic actions and interactions. Pharmacologic and hemodynamic mechanisms underlying the antianginal actions of verapamilB N Singh, C Y Chew, M A Josephson, et al.
Pigment Cell & Melanoma Research|August 18, 2009
Identification of direct transcriptional targets of (V600E)BRAF/MEK signalling in melanomaLeisl M Packer, Philip East, Jorge S Reis-Filho, et al.
Journal of the American College of Cardiology|August 1, 1983
Hemodynamic responses to combined therapy with captopril and hydralazine in patients with severe heart failureB M Massie, M Packer, J T Hanlon, et al.
The New England Journal of Medicine|July 31, 1980
Importance of left ventricular chamber size in determining the response to hydralazine in severe chronic heart failureM Packer, J Meller, N Medina, et al.
The American Journal of Cardiology|June 15, 1995
Role of endothelin in the exercise intolerance of chronic heart failureH Krum, R Goldsmith, M Wilshire-Clement, et al.
The New England Journal of Medicine|November 29, 1979
Rebound hemodynamic events after the abrupt withdrawal of nitroprusside in patients with severe chronic heart failureM Packer, J Meller, N Medina, et al.
The Australasian Journal of Dermatology|February 8, 2012
Folliculosebaceous cystic hamartoma of the ear and periauricular skinVladimir O Osipov, Peter Vincent, Andrew M Packer, et al.
The American Journal of Cardiology|March 1, 1980
Dose requirements of hydralazine in patients with severe chronic congestive heart failureM Packer, J Meller, N Medina, et al.
Pageof 33